Markman Biologics Receives TRIP Letter
Markman Biologics Receives TRIP Letter News provided by Share this article LAS VEGAS, April 26, 2021 /PRNewswire/ -- Markman Biologics Corporation (the "Company") ( https://markmanbiologics.com) today announces they have received our TRIP LETTER (Tissue Reference Group Rapid Inquiry Process). The TRIP response letter was received from the Food and Drug Administration (FDA), and specifically from the Center for Biologics Evaluation and Research (CBER) which provides confirmation of our regulatory status as a 361 HCT/P, and the documentation of that status is what is required to be provided fo...